anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: This study was undertaken to develop a model and perform a preliminary internal validation study of the Scale for Objective Diagnostic Components of Paroxysmal Events (STAMP).
METHODS: We developed STAMP, which builds on the International League Against Epilepsy task force scale for functional seizures with additional categories for epileptic seizures and syncope. We included 200 consecutive referrals to a Dutch tertiary epilepsy center to evaluate seizurelike events. We recorded demographic and clinical data and collected the clinical evaluation at referral and after 3, 6, 9, and 12 months of follow-up. We ascertained the STAMP at each time point and evaluated factors predicting an improvement in STAMP grade during follow-up.
RESULTS: Of the 200 referrals at baseline, 131 were classified as having epileptic seizures, 17 as functional seizures, and three as syncope, and 49 were unclassifiable. STAMP grade at baseline was 4 (absent) in 56 individuals, 3 (circumstantial) in 78, 2 (clinically established) in six, and 1 (documented) in 11. Over time, 62 cases STAMP grades improved, and 23 remained unclassifiable. A refinement of STAMP grade during follow-up was due to successful event recordings in 34 people (30 video-electroencephalographic [EEG] recordings, four tilt table testing), home videos or clinician-witnessed events in 13, and identification of interictal EEG or magnetic resonance imaging abnormalities in seven. An improved STAMP grade after 12 months of follow-up was significantly more likely in those with higher event frequency, unclassifiable events, longer event duration, and a shorter time since the first event and less likely in those with a history suggestive of seizures.
SIGNIFICANCE: This epilepsy service evaluation underscores the crucial role of event recording in improving diagnostic certainty. STAMP may be used to monitor diagnostic performance over time but requires further validation.
PURPOSE: Cancer patients undergoing chemotherapy continue to experience significant fatigue, which affects their quality of life. The present study aims to evaluate the combined effect of comprehensive physical exercise, pranayama (regulated breathing practices of yoga), and dietary support intervention on fatigue in cancer patients undergoing chemotherapy.
METHODS: Non-advanced adult cancer patients undergoing chemotherapy (N = 52) were randomized into the intervention group (N = 26) or control group (N = 26). Fatigue assessment was done using the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale (version 4) at baseline and after 3 months. The intervention group participants practiced physical exercise, slow-paced pranayama and supplemented their diet with an intake of 100 g of millet protein powder (MPP), commonly known as "Sattu" in India. The control group received standard medical care.
RESULTS: A total of 39 patients (N = 13 in the intervention and N = 26 in the control group) were included in the statistical analysis. Within the intervention group, a statistically significant reduction in fatigue (p = 0.002) with a large effect size (d = 2.1) was observed. There was no statistically significant reduction in fatigue within the control group (p = 0.36). The group comparison showed a statistically significant reduction in post-scores of fatigue (p < 0.0001) in the intervention group as compared to the control group with a moderate effect size (R = 0.1). No unintended adverse effects related to the intervention were observed.
CONCLUSION: The results suggest the potential role of integrated physical exercise, pranayama, and dietary support in reducing fatigue in cancer patients undergoing chemotherapy. Further validation with a larger sample size is required.
TRIAL REGISTRATION: CTRI/2022/04/041717 [Registered prospectively on 07/04/2022].
N-of-1 Trial arm: Participants will use the Eureka mobile application and AliveCor device to execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers. Each N-of-1 trial will last a total of 6 weeks and will include up to 3 periods of trigger exposure and 3 periods of trigger elimination with each exposure/elimination period lasting 1 week. Participants will be randomly assigned to start their trial with a period of either trigger exposure or elimination. During each N-of-1 trial, participants will track daily AF duration and severity, daily mood and sleep quality, daily AliveCor tracings and daily trigger exposure. At the end of each trial, participants will be able to review their trial results which will include visualizations of their daily AF symptom and trigger tracking over time. After completing a trial, participants will be instructed to implement any lifestyle changes they deem appropriate based on what they learned from the results of their trial. Participants will implement these changes for a period of 4 weeks during which they will continue to track AF episode duration and severity via the app. At the end of the 4-week lifestyle change period, participants will complete the Atrial Fibrillation Effect on QualiTy of Life survey (AFEQT) and will then have the option of testing another trigger or ending their study participation.

Symptom Surveillance arm: Participants will use the Eureka app and AliveCor device to record daily AF duration and severity, daily AliveCor readings and daily mood and sleep quality for a period of 10 weeks. Participants will be able to visualize their AF, sleep and mood data in real time and will receive a weekly summary of their data via the Eureka app.At the end of the 10-week data tracking period, participants will complete the AFEQT survey and will then have the option of either ending their study participation or crossing over to the N-of-1 trial arm to test their triggers.
Hot pack application was applied to the participants in the hot group to warm the extremities locally after the pre-tests were completed. For the application of hotpack, which is a superficial and moist temperature agent, a Chattanooga ® brand hotpack pad (DJO Global, Chattanooga; CA, USA) with 10 slices and a size of 28 cm x 39 cm was used. The hotpack pad was taken with the help of tongs from the Chattanooga ® brand hot pack boiler (DJO Global, Chattanooga; CA, USA) at 80° temperature and wrapped in a total of 5 layers with the help of 2 towels. A hotpackpad was placed on each knee of the participant. Hotpack pads were applied for 15 minutes in total.
BACKGROUND/AIM: Early detection and prognosis of sepsis in critically ill children is crucial. The aim of this research was to investigate the prognostic ability of pancreatic stone protein (PSP) in validating sepsis and predicting mortality in a prospective observational study.
MATERIALS AND METHODS: In a single-center study, pediatric intensive care unit patients were divided into cohorts of confirmed and suspected sepsis, as well as survivors and nonsurvivors. Patients with positive blood culture growth were considered to have confirmed sepsis, while their negative counterparts were considered to have suspected sepsis. Comparisons were made between complete blood counts, laboratory parameters, mortality indices, and C-reactive protein (CRP), procalcitonin (PCT), and PSP levels. The correlations between PSP and alternative inflammatory markers and mortality indices were then analyzed. The diagnostic and prognostic applicability of PSP for sepsis confirmation and mortality prediction was assessed using receiver operating characteristic curve analysis.
RESULTS: PSP levels were significantly elevated in patients with confirmed sepsis and within the nonsurvivor segment. In confirming sepsis and predicting mortality, PSP outperformed CRP and PCT in terms of sensitivity. It had sensitivity of 95% in diagnosing sepsis at a cut-off level of 50 ng/L, with an area under the curve (AUC) of 0.67 (95% CI: 0.52-0.81), and sensitivity of 92% in predicting mortality, with an AUC of 0.71 (95% CI: 0.56-0.83). In addition, PSP showed significant correlations with CRP, PCT, and mortality scores.
CONCLUSION: PSP is emerging as a highly sensitive marker for confirming sepsis and predicting mortality in critically ill pediatric patients. Incorporating the PSP biomarker into routine clinical practice could potentially improve the management of pediatric sepsis.
All available Emergency and Compassionate PIVSD Occluder subject data from 2011 until the end of 2016 will be utilized to determine technical success and acute survival. All subjects belonging to this cohort must have undergone an attempt to close a post-infarct VSD using the AMPLATZER™ PIVSD Occluder.
INTRODUCTION: Burn patients in rural areas may encounter poorer outcomes associated with barriers to care; however, residence has not been studied in a large sample. The association between rural-versus-urban residence and outcomes after burn was examined using the National Inpatient Sample (NIS) database.
METHODS: Using the 2019 NIS database, patients over 18 years with a primary diagnosis of burn or corrosive injury were included. Level of urbanization was categorized into six groups. Outcomes after burn such as in-hospital mortality, multifactorial shock, prolonged mechanical ventilation, length of stay, and total costs were analyzed after adjusting for demographic factors and hospital characteristics.
RESULTS: We included 4671 records, which represented a weighted population of 23,085 patients. Rural residence was associated with higher percentage of prior transfer but not in-hospital mortality. Compared to the most urbanized counties, encounters from the most rural counties were associated with higher odds of shock (aOR:2.62, 99% CI: 1.04-6.56, p = 0.007).
CONCLUSION: Burn encounters from less urbanized counties did not experience differences in mortality, rates of skin grafting, prolonged mechanical ventilation, length of stay, or overall costs. However, odds of shock were higher among the least urbanized counties. Despite improved triage and transportation systems across the US, disparities and challenges exist for burn patients from rural residence.
Experimental arm = non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O) NIV will intermittently delivered to the patients for at least six hours (cumulative tme of all trials which lasted at least 30 min) during the first 24h after the initiation of treatment. Between each NIV period, the patient will received supplemental oxygen through facial mask to achieve an oxygen saturation level above 94%.
The presence of a microbiome in the urinary system has been established through recent advancements in technology and investigation of microbial communities in the human body. The study of the taxonomic and genomic ecology of microbial communities has been greatly improved by the use of metagenomics. The research in this area has expanded our understanding of microbial ecosystems and shows that the urinary tract contains over 100 species from over 50 genera, with Lactobacillus, Gardnerella, and Streptococcus being the most common. Previous studies have suggested that the microbiota in the urinary tract may play a role in carcinogenesis by causing chronic inflammation and genotoxicity, but more research is needed to reach a definite conclusion. This is a narrative review. We conducted a search for relevant publications by using the databases Medline/PubMed and Google Scholar. The search was based on keywords such as "urinary microbiome," "bladder cancer," "carcinogenesis," "urothelial carcinoma," and "next-generation sequencing." The retrieved publications were then reviewed to study the contribution of the urinary microbiome in the development of bladder cancer. The results have been categorized into four sections to enhance understanding of the urinary microbiome and to highlight its role in the emergence of bladder cancer through alterations in the immune response that involve T-cells and antibodies. The immune system and microbiome play crucial roles in maintaining health and preventing disease. Manipulating the immune system is a key aspect of various cancer treatments, and certain gut bacteria have been linked to positive responses to immunotherapies. However, the impact of these treatments on the urinary microbiome, and how diet and lifestyle affect it, are not well understood. Research in this area could have significant implications for improving bladder cancer treatment and patient outcomes.
PURPOSE: To obtain a plaster capable of imparting a corset effect to a body and good in the use touch by using the laminate of a synthetic resin foam to woven or nonwoven fabric as a support, and subsequently forming an adhesive agent layer on the woven or nonwoven fabric of the support. CONSTITUTION: Woven fabric or nonwoven fabric is attached on one side of a synthetic resin foam (e.g. polyethylene foam), and 5-80wt.% of the whole surface area is fused or bonded. The laminate thus produced is used as support. An adhesive agent layer containing an adhesive agent as a main component is formed on the woven or nonwoven fabric side of the support to prepare the plaster. The fusion is performed by a method comprising e.g. thermally melting the foam and subsequently laminating the woven fabric or nonwoven fabric to the melted surface, and the formation of the adhesive agent is performed e.g. by a solvent-coating method. The plaster exhibits a corset effect, when the plaster is adhered to a diseased site in the state wherein the peelable foam layer is attached.  When the foam layer is peeled, the left plaster can be adhered to a site requiring elasticity, such as a shoulder or joint, without giving a bulky touch or a feeling of physical disorder.
PURPOSE:To provide a fungicide for an incense stick, excellent in its fungicidal effect, free from generation of odor when burnt, not having a special effect on generation of ash and showing other properties, e.g. low generation of soot or charcoal, and to provide an incense stick containing the above-mentioned fungicide. CONSTITUTION:The objective fungicide for an incense stick contains allyl isothiocyanate (AIT), especially cyclodextrin-inclusion compound of AIT as the active component. The objective incense stick contains AIT, especially cyclodextrin-inclusion compound of AIT in an amount of 5 to 200ppm, preferably 20 to 100ppm on AIT base. This incense stick has an excellent fungicidal effect and, therefore, can be stored for a long period. Further, the incense stick is not substantially different from one not containing the fungicide in regard to generation of odor, generation of ash and generation of soot or charcoal. In addition, alpha-to beta-cyclodextrins, a dilower-alkyl (or 2-hydroxy-lower-alkyl)-beta- cyclodextrin, etc., especially beta-cyclodextrin can be used as the cyclodextrin for including AIT.
PURPOSE:To prevent cloudiness after formation of a coating film by adding one or more of methyl salicylate, benzyl acetate, isoamyl acetate, lemon oil and melon oil in a composition for coating teeth comprising shellac as a base. CONSTITUTION:100 pts.wt. of 10-50% solution of shellac in an alcohol is mixed with 0.5-20 pts.wt. of a base improver such as scaly foil paste, 0.1-10 pts.wt. of pigment such as titanium oxide, 5-20 pts.wt. of a cloudiness inhibitor composed of one or more selected from the group consisting of methyl salicylate, benzyl acetate, isoamyl acetate, lemon oil and melon oil and optionally a small amount of pigment, dye, brighter, dispersant, fluoride, etc., to provide a composition for coating a tooth. Since this composition for coating a tooth has excellent peeling resistance, high opacifying effect and excellent gloss, does not cloud for a long period of time and has no toxicity to human body, the composition is suitable as a composition for hiding a discolored tooth and covering a tooth for beauty culture or theatrical purpose.
The present invention relates in a first aspect to a method for treating a subject suffering from cancer, in particular liver cancer. The method comprises administrating synergistic amounts of a Phyllanthus amarus extract and 5-fluorouracil or a prodrug 5 thereof to a subject, in particular a human. In another aspect of the present invention, a method of potentiating the activity of 5-fluorouracil in cancer cells is provided. In a further aspect, the present invention provides a kit comprising the Phyllanthus amarus extract and the 5-fluorouracil or a prodrug thereof. It has been found that the combination treatment with the Phyllanthus amarus extract 10 of the present invention and 5-fluorouracil or a prodrug thereof allows for synergistically potentiating the activity of 5-fluorouracil. Combined administration of Phyllanthus amarus and 5-fluorouracil or a prodrug thereof, thus, represents a highly promising treatment option for treating patients with cancer with enhanced anti-cancer activity of 5-fluorouracil while reducing or preventing resistances.
Patients defined in Scheme 1, tolerating feeds for \>/= 3 days will be studied twice, after i.v. methadone and after enteral methadone after the end of sampling after the first dose. 4-5 samples will be obtained after dose 1 and after dose 2 depending on PMA and weight. Patients will be divided into groups based on PMA..
BACKGROUND: Transjugular intrahepatic portosystemic shunt (TIPS) is an important therapy for complications of portal hypertension but remains underutilised in regional settings.
AIMS: The aim of this study is to explore the demographics, indications, outcomes and complications in patients undergoing TIPS in two regional hepatology centres.
METHODS: Retrospective analysis was undertaken of all patients undergoing TIPS at two regional centres between January 2017 and March 2023. The primary outcome measures were efficacy and complications of TIPS. Patient demographics (such as age, baseline liver severity scores and aetiology of liver disease) and indications for TIPS are detailed.
RESULTS: Forty-eight patients underwent TIPS. Median age was 56 years (interquartile range (IQR): 46-65). The most common indications for TIPS were refractory ascites (n = 17) and failure of secondary prophylaxis of variceal bleeding (n = 13). Cumulative survival at 3 months and 1 year was 93% and 77% respectively. There was no significant difference in outcomes based on TIPS indication. The median number of paracenteses in patients undergoing TIPS for refractory ascites 1 year pre- and post-TIPS were 10 (IQR: 4.5-16) and 2 (IQR: 0-4) respectively (P < 0.001). There were no procedure-related deaths. Inpatient management of liver disease complications had a mean cost of $32 874.67 (SEM: 7779) in 1 year pre-TIPS compared with $12 304.70 (SEM: 3531.1) in 1 year post-TIPS (P < 0.001).
CONCLUSIONS: TIPS is a safe and effective treatment to reduce complications of portal hypertension and can be performed successfully in the regional setting.
This multi-site hybrid Type 1 effectiveness-implementation study conducted in Washington, District of Columbia (DC), Chicago, and Miami-Dade County will evaluate: 1) the effectiveness of providing MOUD with buprenorphine onsite (via telemedicine from a hub buprenorphine clinic) combined with Recovery Guiding in nonmedical community-based settings (the Better Together Integrated Collaborative Community MOUD care model - BT-MOUD) compared to standard-of-care MOUD with buprenorphine provided in the hub buprenorphine clinic only (HC-MOUD Only) and 2) BT-MOUD implementation barriers and facilitators. In the BT-MOUD intervention, community sites serve as "spokes" for telemedicine provision of MOUD by buprenorphine providers based in a "hub" buprenorphine clinic. A trained and supervised Recovery Guide with roots or connections with the community provides manual-guided Recovery Guiding on-site in the community site. Recovery Guiding includes psychoeducation (about OUD and effective buprenorphine MOUD) and behavioral counseling to promote engagement in MOUD with buprenorphine, retention in care, medication adherence, and behavioral change supportive of recovery. In HC-MOUD Only, participants will receive MOUD with buprenorphine and other available services in the hub buprenorphine clinic only. A Peer Outreach Specialist (POS) will assist with outreach and recruitment of all participants across conditions and with maintaining high rates of follow-up in research assessments. This study will test the hypothesis that BT-MOUD is more effective than HC-MOUD Only in retaining Black persons with OUD in MOUD with buprenorphine through six months post-randomization.
A system for generating a refreshment instruction set is disclosed. The system comprises a computing device configured to receive, from a remote device a user selection identifying a nourishment and health condition of user. Computing device determines an alimentary style relating to the user selection. An alimentary style classifier is used where alimentary style classifier inputs the nourishment and outputs an alimentary style. Computing device retrieves a plurality of recipes relating to the alimentary style and classifies the plurality of recipes based on the health condition. Computing device receives the plurality of recipes and, using training data and classification algorithm, a health alimentary classifier is generated. Based on the health condition and the health alimentary classifier, computing device generates refreshment instruction set. Computing device outputs the refreshment instruction and assigns constructed refreshment on a day of the appointment. A method for generating a refreshment instruction set is disclosed.
PURPOSE: An NSCLC cell line with cross-resistance to cetuximab and gefitinib and a method for screening an anticancer agent using the same are provided to ensure excellent therapeutic effect. CONSTITUTION: An NSCLC cell line has a cross-resistance to cetuximab and gefitinib. A method for screening a medicine for treating cancer comprises a step of treating candidate materials to the cell line and checking resistance overcome to cetuximab and gefitinib. The medicine is PI3K/Akt inhibitor. The cancer is lung cancer, breast cancer, or head and neck cancer. The PI3K/Akt inhibitor is a polyclonal antibody or monoclonal antibody to PI3K or Akt. The PI3K/Akt inhibitor is chemical formula 1.
Risk Summary

Although there is no information on the presence of valacyclovir in human milk, its metabolite, acyclovir, is present in human milk following oral administration of valacyclovir. Based on published data, a 500-mg maternal dose of VALTREX twice daily would provide a breastfed child with an oral acyclovir dosage of approximately 0.6 mg/kg/day (see Data). There is no data on the effects of valacyclovir or acyclovir on the breastfed child or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VALTREX and any potential adverse effects on the breastfed child from VALTREX or from the underlying maternal condition.

Data

Following oral administration of a 500-mg dose of VALTREX to 5 lactating women, peak acyclovir concentrations (Cmax) in breast milk ranged from 0.5 to 2.3 times (median 1.4) the corresponding maternal acyclovir serum concentrations. The acyclovir breast milk AUC ranged from 1.4 to 2.6 times (median 2.2) maternal serum AUC. A 500-mg maternal dose of VALTREX twice daily would provide a breastfed child with an oral acyclovir dosage of approximately 0.6 mg/kg/day. Unchanged valacyclovir was not detected in maternal serum, breast milk or infant urine.